PCSK9 and LDLR

Number of citations of the paper that reports this interaction (PubMedID 17435765)
119

Data Source:
HPRD (in vitro)

		PCSK9	LDLR
Description		proprotein convertase subtilisin/kexin type 9	low density lipoprotein receptor
Image
GO Annotations	Cellular Component	Extracellular Region Extracellular Space Cytoplasm Lysosome Lysosomal Membrane Early Endosome Late Endosome Endoplasmic Reticulum Endoplasmic Reticulum Lumen Rough Endoplasmic Reticulum Golgi Apparatus Plasma Membrane Cell Surface COPII-coated ER To Golgi Transport Vesicle Extrinsic Component Of External Side Of Plasma Membrane Endolysosome Membrane Perinuclear Region Of Cytoplasm PCSK9-LDLR Complex PCSK9-AnxA2 Complex	Cell Lysosome Early Endosome Late Endosome Golgi Apparatus Plasma Membrane Integral Component Of Plasma Membrane Clathrin-coated Pit External Side Of Plasma Membrane Cell Surface Endosome Membrane Membrane Basolateral Plasma Membrane Clathrin-coated Endocytic Vesicle Membrane Low-density Lipoprotein Particle Endolysosome Membrane Somatodendritic Compartment Receptor Complex Apical Part Of Cell Sorting Endosome PCSK9-LDLR Complex
	Molecular Function	RNA Binding Serine-type Endopeptidase Activity Protein Binding Sodium Channel Inhibitor Activity Low-density Lipoprotein Particle Binding Receptor Inhibitor Activity Apolipoprotein Binding Very-low-density Lipoprotein Particle Binding Apolipoprotein Receptor Binding Protein Self-association Low-density Lipoprotein Particle Receptor Binding Very-low-density Lipoprotein Particle Receptor Binding	Amyloid-beta Binding Virus Receptor Activity Protease Binding Low-density Lipoprotein Particle Receptor Activity Calcium Ion Binding Protein Binding Low-density Lipoprotein Particle Binding Very-low-density Lipoprotein Particle Receptor Activity Clathrin Heavy Chain Binding Identical Protein Binding
	Biological Process	Kidney Development Liver Development Negative Regulation Of Receptor Recycling Positive Regulation Of Receptor Internalization Triglyceride Metabolic Process Phospholipid Metabolic Process Apoptotic Process Lysosomal Transport Cholesterol Metabolic Process Cellular Response To Starvation Regulation Of Signaling Receptor Activity Negative Regulation Of Low-density Lipoprotein Particle Clearance Protein Autoprocessing Neurogenesis Neuron Differentiation Low-density Lipoprotein Particle Receptor Catabolic Process Positive Regulation Of Low-density Lipoprotein Particle Receptor Catabolic Process Cellular Response To Insulin Stimulus Low-density Lipoprotein Particle Clearance Lipoprotein Metabolic Process Cholesterol Homeostasis Regulation Of Neuron Apoptotic Process Positive Regulation Of Neuron Apoptotic Process Post-translational Protein Modification Cellular Protein Metabolic Process Negative Regulation Of Low-density Lipoprotein Particle Receptor Binding Negative Regulation Of Low-density Lipoprotein Receptor Activity Negative Regulation Of Receptor-mediated Endocytosis Involved In Cholesterol Transport Negative Regulation Of Signaling Receptor Activity Negative Regulation Of Sodium Ion Transmembrane Transporter Activity	Lipid Metabolic Process Endocytosis Receptor-mediated Endocytosis Phagocytosis Long-term Memory Cholesterol Metabolic Process Positive Regulation Of Gene Expression Negative Regulation Of Gene Expression Positive Regulation Of Triglyceride Biosynthetic Process Regulation Of Phosphatidylcholine Catabolic Process Phospholipid Transport Intestinal Cholesterol Absorption Cholesterol Transport Plasma Lipoprotein Particle Clearance Chylomicron Remnant Clearance Low-density Lipoprotein Particle Clearance High-density Lipoprotein Particle Clearance Lipoprotein Catabolic Process Cholesterol Homeostasis Viral Entry Into Host Cell Artery Morphogenesis Positive Regulation Of Inflammatory Response Regulation Of Protein Metabolic Process Negative Regulation Of Protein Metabolic Process Membrane Organization Response To Caloric Restriction Negative Regulation Of Astrocyte Activation Cholesterol Import Cellular Response To Fatty Acid Cellular Response To Low-density Lipoprotein Particle Stimulus Receptor-mediated Endocytosis Involved In Cholesterol Transport Regulation Of Cholesterol Metabolic Process Amyloid-beta Clearance Amyloid-beta Clearance By Cellular Catabolic Process Negative Regulation Of Microglial Cell Activation Positive Regulation Of Lysosomal Protein Catabolic Process Negative Regulation Of Amyloid Fibril Formation
Pathways		Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) VLDLR internalisation and degradation Post-translational protein phosphorylation LDL clearance	Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis Chylomicron clearance Chylomicron clearance LDL clearance Retinoid metabolism and transport
Drugs		Alirocumab	Porfimer sodium
Diseases		Hypercholesterolemia, autosomal dominant; Hyperlipoproteinemia, type IIa	Hypercholesterolemia, autosomal dominant; Hyperlipoproteinemia, type IIa
GWAS		Blood protein levels ( 30072576) Cholesterol, total ( 24097068 28270201 25961943 20686565 26582766) Coronary artery disease ( 29212778 30104761 26343387) Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease) ( 28714975) Coronary heart disease ( 21378990) LDL cholesterol ( 23726366 24097068 24507774 18193043 18193044 20864672 26160806 19060906 30275531 25961943 20686565 26582766) LDL cholesterol levels ( 28334899 30698716) LDL cholesterol levels in current drinkers ( 30698716) LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716) LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716) LDL cholesterol levels x long total sleep time interaction (2df test) ( 31719535) LDL cholesterol levels x short total sleep time interaction (2df test) ( 31719535) Lipid metabolism phenotypes ( 22286219) Low density lipoprotein cholesterol levels ( 30718733) Medication use (HMG CoA reductase inhibitors) ( 31015401) Metabolite levels ( 23823483 22916037) Metabolite levels (lipoprotein measures) ( 27005778) Mitochondrial DNA copy number ( 30704525) Myocardial infarction ( 26343387) Myocardial infarction (early onset) ( 19198609) Plasma proprotein convertase subtilisin/kexin type 9 levels in stable coronary artery disease ( 29748315) Response to statins (LDL cholesterol change) ( 22331829) Serum metabolite levels ( 31636271) Serum metabolite levels (CMS) ( 31636271) Total cholesterol levels ( 30718733 28334899 29403010 30275531)	Abdominal aortic aneurysm ( 27899403 24046328) C-reactive protein levels or LDL-cholesterol levels (pleiotropy) ( 27286809) Cardiovascular disease risk factors ( 21943158) Carotid intima media thickness ( 21909108) Carotid plaque ( 30510157) Cholesterol, total ( 24097068 19060911 25961943 20686565 26582766) Coronary artery disease ( 29212778 24262325 30104761 26343387) Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease) ( 28714975) Coronary artery disease or ischemic stroke ( 24262325) Coronary artery disease or large artery stroke ( 24262325) Coronary heart disease ( 21378990) Cortisol levels (saliva) ( 28843169) Disorders of lipid metabolism ( 30166351) HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716) Ischemic stroke ( 29531354) LDL cholesterol ( 23726366 24097068 18193043 18193044 20864672 19060906 19060910 19060911 30275531 21347282 25961943 20686565 26582766) LDL cholesterol levels ( 28334899 30698716) LDL cholesterol levels in current drinkers ( 30698716) LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716) LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716) LDL cholesterol levels x long total sleep time interaction (2df test) ( 31719535) LDL cholesterol levels x short total sleep time interaction (2df test) ( 31719535) Lipid metabolism phenotypes ( 22286219 19936222) Lipoprotein phospholipase A2 activity in cardiovascular disease ( 28753643) Lipoprotein-associated phospholipase A2 activity and mass ( 22003152) Low density lipoprotein cholesterol levels ( 30911093 29403010 31217584) Medication use (agents acting on the renin-angiotensin system) ( 31015401) Medication use (antithrombotic agents) ( 31015401) Medication use (HMG CoA reductase inhibitors) ( 31015401) Medication use (salicylic acid and derivatives) ( 31015401) Metabolite levels ( 21909109 23823483 22916037) Metabolite levels (lipoprotein measures) ( 27005778) Myocardial infarction ( 26343387) Myocardial infarction (early onset) ( 19198609) Parental longevity (combined parental attained age, Martingale residuals) ( 29227965) Peripheral artery disease ( 31285632) Serum metabolite levels ( 31636271) Serum metabolite levels (CMS) ( 31636271) Stroke ( 29531354) Total cholesterol levels ( 28334899 30911093 29403010 31217584)
Interacting Genes		4 interacting genes: BACE1 BIRC2 LDLR TMED5	14 interacting genes: AP1M2 APOB APOE CD36 CREBBP DAB1 DAB2 HSPA5 LDLRAP1 LRPAP1 MAP4 PCSK9 PF4 SNX17
Entrez ID		255738	3949
HPRD ID		07080	06091
Ensembl ID		ENSG00000169174	ENSG00000130164
Uniprot IDs		Q8NBP7	A0A024R7D5 P01130
PDB IDs		2P4E 2PMW 2QTW 2W2M 2W2N 2W2O 2W2P 2W2Q 2XTJ 3BPS 3GCW 3GCX 3H42 3M0C 3P5B 3P5C 3SQO 4K8R 4NE9 4NMX 4OV6 5OCA 5VL7 5VLA 5VLH 5VLK 5VLL 5VLP 6E4Y 6E4Z 6F5G 6MV5 6OLZ 6OM0 6OM7 6U26 6U2N 6U2P 6U36 6U38 6U3X	1AJJ 1D2J 1F5Y 1F8Z 1HJ7 1HZ8 1I0U 1IJQ 1LDL 1LDR 1LRX 1N7D 1XFE 2FCW 2KRI 2LGP 2M7P 2MG9 2W2M 2W2N 2W2O 2W2P 2W2Q 3BPS 3GCW 3GCX 3M0C 3P5B 3P5C 3SO6 4NE9 5OY9 5OYL
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?